Amgen Onc vs Onyx

Quote
Anonymous said:
Our ONYX drug extends life....what does Neulasta do?


The results from ASPIRE (abstract 79) will be featured during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition press briefing on Saturday, December 6 at 8 a.m. PT and were published in the New England Journal of Medicine. Keith Stewart, M.B., Ch.B., dean for research at Mayo Clinic in Arizona and principal investigator will present these results in an oral session at ASH on Sunday, December 7 at 12 p.m. PT.

Secondary endpoints, which are being presented for the first time, included overall survival (OS), overall response rate (ORR), duration of response (DOR), health-related quality of life (HR-QoL) measures and safety. While the data for median OS are not yet mature based on the prespecified statistical boundary at the interim (p=0.005), the analysis showed a trend in favor of KRd compared with Rd ()p=0.018, two-sided p=0.04). Patients will continue to be monitored for OS. The ORR was 87.1 percent with KRd and 66.7 percent with Rd ()p<0.0001, two-sided p<0.001). In the KRd and Rd groups, 14 percent versus 4.3 percent of patients achieved a stringent complete response, a measurement indicating superior depth of response. Median DOR was 28.6 months (KRd) and 21.2 months (Rd). KRd consistently improved Global HR-QoL compared with Rd over 18 cycles of treatment (one-sided p=0.0001, two-sided p<0.001).

"Nearly all patients with multiple myeloma experience a relapse following treatment, underscoring the need for new options that not only extend the time patients live without their disease progressing, but also improve the depth and duration of a response to treatment," said Dr. Stewart. "The combination of carfilzomib, lenalidomide and low-dose dexamethasone generates deep and durable responses, provides a clinically meaningful improvement in progression-free survival and promises to be an important advancement in the treatment of myeloma."
Click to expand...

Block fooking buster.
 




















Top Bottom
Back
Quote